All In Biotech

NDA 020583 · Bausch and Lomb

Lotemax

Loteprednol Etabonate · Ophthalmic

Novel

Last checked: Nov 19, 2026Latest source record: Dec 16, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Mar 9, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

16 Phase 3, 0 recruiting

FAERS reports

4,307

1,582 serious, 124 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 28, 2025.

INDICATIONS AND USAGE Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LOTEMAX · LOTEPREDNOL ETABONATE 0.5% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain600
  • eye irritation483
  • off label use353
  • drug ineffective329
  • vision blurred312
  • ocular hyperaemia279
  • headache230
  • fatigue216
  • dry eye180
  • pain169
  • nausea168
  • eye swelling153

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200515
200622
200716
200833
200965
2010107
201177
2012137
201388
2014152
2015275
2016388
2017341
2018318
2019350
2020277
2021255
2022291
2023286
2024305
2025300
2026201

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lotemax (Loteprednol Etabonate)

2024 spending

$9.5M

Beneficiaries

13,977

25,078 claims

Per beneficiary

$683

$88.65 per unit

View as table
YearSpending
2020$32,882,502
2021$18,035,919
2022$12,204,111
2023$10,831,409
2024$9,542,146

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.